Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Lapatinib + Temozolomide + Radiation for Glioblastoma
Recruiting1 awardPhase 2
Los Angeles, California
This trial is for patients with newly diagnosed glioblastoma multiforme. The standard treatment for this cancer is radiation therapy and the chemotherapy agent Temozolomide. However, the study drug Lapatinib has not been FDA approved for use in brain tumor treatment. This study is testing to see if Lapatinib is safe and effective when given in combination with radiation therapy and Temozolomide.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.